ImmuPharma plc (ALIMM.BR) Comparison with companies in other sectors?

ImmuPharma plc has a share price of N/A. You can analyze ImmuPharma plc (ALIMM.BR) competitors across different market sectors through stock heatmaps.

What are ALIMM.BR's NET and operating margins?

ImmuPharma plc (ALIMM.BR) operating margin is around -55.38, and net profit margin is approximately -54.16 as of the latest reports.

In what way does ALIMM.BR's earnings per share (EPS) trend reflect its financial momentum?

ImmuPharma plc (ALIMM.BR) EPS is -0.04 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for ImmuPharma plc is -2.23, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for ImmuPharma plc?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for ImmuPharma plc like P/E which is -2.27, P/B which is 1.61, and PEG which is -0.03. Compare them with sector averages to evaluate if the stock is priced fairly.

ImmuPharma plc

ALIMM.BR•EURONEXT

Healthcare

Biotechnology

€0.09

€0.00(0.00%)

Fundamental Analysis of ImmuPharma plc (ALIMM.BR)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-0.04

P/E Ratio

-2.23

ROE

-0.92%

Net Margin

-54.16%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$0.00

Shares OutstandingTotal number of shares issued

Book Value/ShareNet worth per share

$0.05

Revenue/ShareAnnual revenue per share

$0.001

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-0.04

Net MarginNet income as percentage of revenue

-5415.72%

Operating MarginOperating income as percentage of revenue

-5538.42%

ROEReturn on shareholders' equity

-91.93%

ROAReturn on total assets

-62.84%

ROCEReturn on capital employed

-72.66%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-0.02

Cash/ShareCash and equivalents per share

$0.03

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for ALIMM.BRFinancial Ratios Analysis details for ALIMM.BR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for ALIMM.BRSector Benchmarking details for ALIMM.BR are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for ImmuPharma plc Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of ImmuPharma plc. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account ImmuPharma plc's unique business strengths and challenges.

Key Financial Metrics for ImmuPharma plc

For ImmuPharma plc, essential financial indicators include EPS -0.04, PE -2.23, and ROE -0.92. These key ratios reveal insights into ImmuPharma plc's profitability, valuation, and operational health. Understanding these metrics enables you to compare ImmuPharma plc with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of ImmuPharma plc

Metrics like Net Margin -5415.72% and ROA -62.84% shed light on how well ImmuPharma plc is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether ImmuPharma plc can sustain its operations and continue growing in the future.

Valuation and Market Position of ImmuPharma plc

Using ratios such as P/B Ratio 1.61 and PEG Ratio -0.03, investors can assess whether ImmuPharma plc is appropriately valued based on its financials and growth potential. These figures, combined with ImmuPharma plc's market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for ImmuPharma plc

Financial health indicators, such as Debt/Equity Ratio 0.07 and Cash Flow $-0.02, provide a snapshot of ImmuPharma plc's ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like ImmuPharma plc, is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for ImmuPharma plc

Investing in ImmuPharma plc based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at ImmuPharma plc focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;